Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amplia Therapeutics Ltd. has successfully completed the allotment of over 67 million shares at $0.115 each, raising $13 million through an institutional placement. This capital raise bolsters Amplia’s financial position as it continues its research and trials, particularly in developing its promising cancer drug, narmafotinib. The company’s strategic focus on FAK inhibitors positions it attractively in the evolving cancer treatment market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.